This review highlights the potential of neuromodulation techniques in reducing inflammation and arrhythmia burden, suggesting a new direction for anti-arrhythmic therapies.
Cardiac autonomic modulation has emerged as a novel therapeutic frontier for atrial and ventricular arrhythmias, addressing the limitations of conventional anti-arrhythmic drugs, ablation, and device therapies. This review summarizes recent progress in neuromodulation, focusing on mechanistic foundations, clinical applications, safety considerations, and future directions. Neuromodulatory techniques such as ganglionated plexus ablation, vagus nerve stimulation, renal denervation, and stellate ganglion modulation have shown potential to restore autonomic balance, reduce inflammation, and lower arrhythmic burden in refractory and inflammation-associated conditions. Advances in artificial intelligence-assisted mapping, high-resolution imaging, and closed-loop biofeedback systems are improving the precision and adaptability of these therapies. Despite encouraging results, translation remains limited by incomplete mechanistic understanding, anatomical variability, and lack of standardized protocols or objective biomarkers. Rigorous randomized trials and long-term studies are required to confirm durability and safety. The integration of neuromodulation with digital, imaging, and structural rhythm strategies represents a major step toward personalized electrophysiology and the next generation of arrhythmia management.
No takes yet. Share an insight, caveat, or question.
Tran et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: